LONG-TERM CLINICAL AND ENDOSCOPIC OUTCOMES IN TRUE NORTH WEEK 52 CLINICAL REMITTERS OVER 3 YEARS OF TREATMENT WITH OZANIMOD: AN INTERIM ANALYSIS OF THE TRUE NORTH OPEN-LABEL EXTENSION STUDY

Maria T. Abreu

UEG Week Copenhagen 2023 | Poster

IBD

October 17, 2023

Interim analysis of the True North open-label extension demonstrates sustained efficacy of ozanimod over 146 weeks in ulcerative colitis patients who achieved clinical response at week 52, with higher efficacy rates in those who achieved remission.

KEY POINTS

- Among 131 patients entering the open-label extension as week-52 clinical responders on continuous ozanimod, 63% were in clinical remission and these clinical remitters achieved higher rates of efficacy outcomes at weeks 46 and 94 than nonremitters.
- At open-label extension week 94, clinical remitters achieved clinical remission in 94.4% of cases, clinical response in 75.9%, endoscopic improvement in 78.6%, and corticosteroid-free remission in 74.1%.
- Clinical nonremitters at week 52 achieved lower but still substantial efficacy at week 94: clinical remission 85.2%, clinical response 55.6%, endoscopic improvement 63.3%, and corticosteroid-free remission 55.6%.
- Durability of response from week 46 to week 94 was maintained in most patients across all efficacy endpoints, ranging from 66% to 80% depending on endpoint and remission status.
- Clinical remitters had lower prior TNF inhibitor use (25.3%) compared with nonremitters (43.8%), though baseline demographics and disease characteristics were otherwise generally similar between groups.

VIEW THIS CONTENT ON GUTFLIX

https://gutflix.eu/search/d/5432cd3e-743b-11ee-a79e-0242ac140004

AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.